Delivery Order SPE2DB22D3016-SPE2DB25FBCV4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This firm fixed-price delivery order, valued at $35,744.56, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors valued at $7,436.99. This competitively awarded, firm fixed-price contract is classified as a delivery order with an ultimate completion date of August 18, 2025, and involves performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens valued at $8,763.90. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a $4,888.38 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pen form with an ultimate completion date of August 25, 2025. This competitive award, issued without set-aside designation, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be performed at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBCV4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries no small business set-aside designation. This delivery order is executed under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical support mechanism for military healthcare systems globally. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical vendor, leverages this prime contract vehicle to supply branded and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Zepbound order supports diabetes treatment needs within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 7/23/25 |